Persistent AF ablation demands precision, lesion integrity, and an efficient workflow. This expert-led webinar brought together leading electrophysiologists to share clinical evidence, real-world strategies and the latest innovations that drove better outcomes.
Prof Serge Boveda opened the session with his keynote Setting the Stage: Innovations and Insights in AF Ablation, before unveiling key results from ADVANTAGE AF Phase I & II: Safety, Efficacy, and Beyond. Prof Daniel Scherr took participants inside a recorded case, Persistent AF and PWA Strategy: From Mapping to Optimisation, demonstrating how FARAVIEW™ supported lesion delivery mastery in the clinical workflow. Prof Christian Sohns then spotlighted Rethinking Lesion Depth: A New Frontier in Focal Ablation Technology.
The session closed with The Final Pulse: Debating Clinical Decisions in Persistent AF, a dynamic Q&A where the faculty tackled the audience’s most pressing questions.
Attendees had the opportunity to enhance their approach to persistent AF ablation and gain actionable insights from world-class experts.
EP-2331801-AA
FARAPULSE™ PFA Platform - CE 0459. Use of FARAPULSE™ for treatment of Persistent AF is pending CE Mark.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. ©2025 Boston Scientific Corporation or its affiliates. All rights reserved.
